(NYSE: OGN) Organon & Co's forecast annual revenue growth rate of 0.52% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Organon & Co's revenue in 2024 is $6,263,000,000.On average, 2 Wall Street analysts forecast OGN's revenue for 2024 to be $1,616,957,984,086, with the lowest OGN revenue forecast at $1,615,275,884,362, and the highest OGN revenue forecast at $1,618,640,083,811. On average, 3 Wall Street analysts forecast OGN's revenue for 2025 to be $1,626,258,103,839, with the lowest OGN revenue forecast at $1,619,698,426,190, and the highest OGN revenue forecast at $1,632,390,865,601.
In 2026, OGN is forecast to generate $1,624,547,883,907 in revenue, with the lowest revenue forecast at $1,598,301,504,163 and the highest revenue forecast at $1,642,281,509,725.